Research programme: small molecule therapeutics - Algiax Pharmaceuticals

Drug Profile

Research programme: small molecule therapeutics - Algiax Pharmaceuticals

Alternative Names: AP 325; AP-19; AP-2; AP-3; AP-4; AP-61; AP-778; AP-8

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Algiax Pharmaceuticals
  • Class Imidazoles; Small molecules; Triazines
  • Mechanism of Action GABA A receptor modulators; Type 4 cyclic nucleotide phosphodiesterase modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Cognition disorders; Type 1 diabetes mellitus
  • No development reported Neuropathic pain

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Neuropathic-pain in Germany (PO)
  • 10 Aug 2017 Research programme: small molecule therapeutics - Algiax Pharmaceuticals is available for licensing as of 10 Aug 2017. http://algiax.de/
  • 04 Aug 2017 Preclinical trials in Cognition disorders in Germany (unspecified route) (Algiax pipeline, August 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top